Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard treatment for this disease and is associated with modest prolongation of survival, there is an urgent need for novel treatments for castration-resistant prostate canc...
Saved in:
Main Authors: | Takahiro Inoue, Osamu Ogawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Prostate Cancer |
Online Access: | http://dx.doi.org/10.1155/2011/647987 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Therapeutics to Treat Castrate-Resistant Prostate Cancer
by: Ömer Acar, et al.
Published: (2013-01-01) -
New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01) -
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
by: Jennifer H. Gunter, et al.
Published: (2012-01-01) -
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01) -
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)